Evidence Level I Exists — But It Does Not Resolve in Cerebrolysin's Favor
Cerebrolysin is unusual among compounds in this hub: it has been the subject of multiple randomized controlled trials and a 2023 Cochrane systematic review — the highest tier of evidence this platform tracks. That distinguishes it from Level V preclinical-only compounds. But having Level I evidence is not the same as having favorable Level I evidence. The 2023 Cochrane review (Ziganshina et al., updating a prior 2010/2020 review) found moderate-certainty evidence of no significant mortality benefit in acute ischemic stroke, alongside a roughly doubled risk of non-fatal serious adverse events compared to placebo. This profile presents that finding without softening it, alongside the narrower, more supportive CARS pooled-trial data in moderate-to-severe stroke recovery specifically.
International Regulatory Context
Widely Approved Abroad · Not FDA-Approved · EVER Pharma (Austria)
Manufacturer & Approval Footprint
EVER Pharma (Austria) — Proprietary Biologic
Cerebrolysin is manufactured by EVER Pharma using a proprietary enzymatic-cleavage process applied to purified porcine brain tissue; no generic or bioequivalent version exists because the process itself — not a single molecular entity — defines the product. It carries marketing approval in a substantial number of international markets, prominently including Russia, China, Austria, Germany, and other parts of Eastern Europe and Asia, for stroke, traumatic brain injury, vascular dementia, and Alzheimer's disease. Exact country counts vary across secondary sources; we intentionally avoid citing a precise figure without a primary EVER Pharma regulatory filing to verify it against.
Not FDA-approved in the United States
US Status
Research / Investigational Preparation Only
No FDA New Drug Application or Biologics License Application has been approved for Cerebrolysin. In the US it is discussed and used as a research/investigational preparation, typically sourced through compounding channels. Because it is a foreign-manufactured multi-component biological rather than a single synthesized peptide, buyers face materially higher counterfeit and authenticity risk than with synthetic single-sequence research peptides — addressed in the Scam & Quality Warnings section below.
No FDA IND on record for this indication set
Not a Single Peptide — A Standardized Biological Mixture
Multi-Component Preparation · Closer to a Biologic Than a Research Peptide
Every other compound in this hub is a single, defined amino acid sequence. Cerebrolysin is fundamentally different — and that difference matters for how it should be evaluated, sourced, and discussed with a physician.
Active Composition — Low-Molecular-Weight Fraction (<10 kDa)
Why This Matters for Evaluation: A defined single peptide can, in principle, be assayed for identity and purity against a reference standard. A standardized biological mixture cannot be verified the same way — authenticity checks rely on manufacturer lot tracking rather than independent structural confirmation. This is a meaningfully different risk profile than a synthetic research peptide, and it is also why no generic or "Cerebrolysin-equivalent" compounded product can be assumed equivalent to the EVER Pharma original, regardless of manufacturer claims.
Cerebrolysin's proposed mechanism is broader and less molecularly precise than single-receptor peptides in this hub — a consequence of it being a mixture of multiple bioactive fragments rather than one ligand acting on one receptor.
Primary Proposed Mechanism
Neurotrophic Factor Mimicry
Active fragments are proposed to mimic endogenous neurotrophic factors (BDNF, GDNF, NGF, CNTF), supporting neuron survival, dendritic growth, and synaptic plasticity signaling downstream of neurotrophin receptors.
Central hypothesis — not a single confirmed receptor
Neuroprotection
Reduced Excitotoxicity & Oxidative Stress
Animal and cell-culture data suggest reduced glutamate-mediated excitotoxic injury, reduced oxidative stress markers, and reduced apoptotic signaling in injured neurons following ischemic or traumatic insult.
Preclinical — supports the rationale, not proof of clinical benefit
Neurogenesis Support
Hippocampal Neurogenesis (Animal Models)
Rodent studies report increased hippocampal neurogenesis and synaptic density measures following Cerebrolysin administration post-injury. Human translation of this specific finding has not been directly confirmed.
Animal model data only
Immune Modulation
Microglial Phenotype Shift
Proposed shift of activated microglia away from pro-inflammatory phenotypes toward a more reparative state, potentially reducing secondary neuroinflammatory injury after stroke or TBI.
Mechanistic hypothesis
Delivery Property
Blood-Brain Barrier Penetration
The <10 kDa active fraction is small enough to cross the blood-brain barrier — a delivery advantage over full-length neurotrophic proteins (e.g., recombinant BDNF), which generally cannot.
Distinguishing pharmacokinetic property
Research-Integrity Caveat: Portions of the broader neurotrophic-factor and Alzheimer's-model preclinical literature — the general scientific context this mechanism draws on, not Cerebrolysin's own randomized trials — have been affected by data-integrity investigations at contributing institutions between 2024 and 2026. This is a reason for appropriate added caution when weighing mechanistic claims in this space generally. It does not itself invalidate the CARS/CAPTAIN human trial data discussed below, which stands on its own methodology.
Routes of Administration
IM (Cognitive-Optimization Protocols) vs. IV (Clinical Stroke/TBI Protocols)
Cerebrolysin has no oral, intranasal, or self-administered low-volume subcutaneous form. Both established routes require either clinical administration or, for the lower-volume IM route, careful technique — this is not an intranasal or micro-dose compound.
Intravenous Infusion — Clinical Stroke/TBI Trials
Higher-volume dosing (20–50 mL) used in the published CARS and CAPTAIN trial protocols
Administered in a clinical/hospital infusion setting under medical supervision — not a self-administration route
The route used in essentially all of the RCT evidence reviewed below
Intramuscular Injection — Lower-Volume Protocols
Lower per-dose volume than IV infusion; discussed in the research-compound literature for cognitive-optimization contexts distinct from the clinical stroke/TBI indication
Volume and viscosity require intramuscular technique — not subcutaneous — with real injection-site reaction risk
This use case has not been evaluated in a randomized trial; it is extrapolated from the clinical-population data, not confirmed in healthy adults
Clinical Evidence Review
Cochrane 2023 · CARS-1/CARS-2 Pooled Analysis · CAPTAIN I & II
Level I · Cochrane Systematic Review
Cerebrolysin for Acute Ischemic Stroke — 2023 Cochrane Review
Ziganshina LE et al. · Cochrane Database of Systematic Reviews 2023 (CD007026) — updating the 2010/2020 versions
Pooled multiple randomized controlled trials of Cerebrolysin in acute ischemic stroke against placebo/standard care.
Primary finding: moderate-certainty evidence of no significant reduction in death or dependency from Cerebrolysin treatment.
Safety finding: approximately doubled risk of non-fatal serious adverse events in the Cerebrolysin arm compared to control — a materially cautionary signal, not a neutral one.
This is the single most important data point for any patient-facing discussion of Cerebrolysin — it represents the highest tier of evidence available and it is not favorable for the stroke indication as a whole.
Level Ib · Pooled RCT Analysis
CARS-1 / CARS-2 Pooled Analysis — Moderate-to-Severe Stroke Motor Recovery
Muresanu DF et al. · Pooled analysis, 2017 — CARS-2 exists only within this pooled publication, not as a standalone trial report
Randomized, placebo-controlled trials specifically in patients with moderate-to-severe ischemic stroke (a narrower population than the Cochrane review's overall pool).
Reported improved motor recovery outcomes in this specific subgroup — the basis for Cerebrolysin's inclusion in some Eastern European and Asian stroke rehabilitation guidelines.
Editorial note: this more favorable, narrower finding coexists with the broader Cochrane review's null/cautionary result — the two are not contradictory once population differences (all-severity vs. moderate-to-severe) are accounted for, but neither should be cited without the other.
Level Ib · RCT
CAPTAIN I & II — Moderate Traumatic Brain Injury
Multi-site RCTs in moderate TBI populations
Evaluated neurological recovery, executive function, and quality-of-life measures following moderate TBI.
Reported improvements favoring Cerebrolysin over placebo on select outcome measures in this population.
TBI evidence has not been synthesized in a dedicated Cochrane review at the same rigor as the stroke literature — treat as a narrower, less independently verified evidence base than the stroke Cochrane review above.
Level IIb · Systematic Reviews
Vascular Dementia & Alzheimer's Disease — Adjunct Use
Multiple systematic reviews, cognitive and global-function endpoints
Reviews report modest cognitive and global-function improvements as an adjunct in vascular dementia and Alzheimer's populations.
Not characterized as a disease-modifying agent by any reviewing body; effect sizes are described as real but bounded.
Cognitive-optimization use in healthy adults — the use case most relevant to a research-compound audience — is extrapolated from these clinical populations and has not been independently studied in healthy subjects.
How to Read the Cerebrolysin Evidence Honestly
Real trials exist — and the highest-tier synthesis is not favorable. The 2023 Cochrane review is exactly the kind of evidence this platform's Level I designation is meant to reward, and its headline finding is "no benefit, more harm" for acute ischemic stroke broadly. That should not be minimized because narrower subgroup data (CARS pooled analysis) looks better.
CARS-2 is not an independent trial report. It exists only inside the 2017 pooled CARS-1/CARS-2 publication — cite it as such, not as two separately replicated studies.
The healthy-adult cognitive-optimization use case has zero direct trial support. Every study above was conducted in stroke, TBI, or dementia populations with active neurological injury or degeneration — not in healthy adults seeking cognitive enhancement. This is an extrapolation, and it should be presented as one.
Editorial position: Cerebrolysin should be discussed as a compound with genuine, if mixed, RCT-level human evidence in specific neurological injury populations — and essentially no direct evidence in the healthy-adult context most research-compound users are considering it for. The doubled serious-adverse-event signal from the Cochrane review deserves equal billing with any positive subgroup finding.
Cerebrolysin vs. Other Cognitive Hub Compounds
Evidence Tier & Route Comparison
Compound
Evidence Level
Route
Human RCT Data
Regulatory Status
Cerebrolysin
Level I
IM / IV only
Yes — mixed/unfavorable overall
Approved abroad; not FDA-approved
Semax
Level IIb
Intranasal
Yes — Russian Phase II/III
Russian pharma approved; not FDA-approved
Selank
Level IIb
Intranasal
Small open-label only
Russian pharma approved; not FDA-approved
Dihexa
Level V
Oral
None — preclinical only
Not FDA-approved; no foreign approval identified
Pinealon
Level V
Intranasal
None — preclinical only
Not FDA-approved; unconfirmed foreign registration
Because Cerebrolysin is a multi-component biological rather than a single synthesized peptide, standard peptide-authenticity checks (mass spectrometry against a known single sequence) do not apply the same way. Sourcing and storage verification are proportionally more important.
❄️
Cold Chain
Refrigerated Shipping Required
Authentic EVER Pharma product ships refrigerated. Room-temperature shipping of a product represented as Cerebrolysin is a significant red flag and grounds to reject the shipment.
🧪
Packaging Format
Single-Use Glass Ampoules Only
Authentic product is supplied in tamper-evident, single-use glass ampoules with lot-specific tracking. Multi-dose vials marketed as "Cerebrolysin" are inconsistent with EVER Pharma's actual packaging and warrant skepticism.
📋
Verification
Lot Number Confirmation
EVER Pharma can confirm authenticity of genuine lot numbers directly. Country-of-origin claims other than Austria (e.g., unverified "Made in China/India Cerebrolysin") are inconsistent with the genuine manufacturing process.
Counterfeit Risk Is Well-Documented: Cerebrolysin has substantiated counterfeit issues in research-chemical sales channels, more so than most single-sequence synthetic peptides on this site. This platform does not provide sourcing or vendor guidance; any decision to obtain this compound should go through a licensed physician or pharmacy able to verify chain of custody.
Investigational Dosing — As Used in Published Clinical Trials
Clinical Trial Protocols Under Medical Supervision · Not a Self-Administration Guide
This Section Describes Trial Protocols, Not a Home-Use Regimen: Every dose below was administered in a clinical or hospital setting as part of a supervised research protocol. Cerebrolysin's real seizure-threshold, allergy, and dose-volume considerations make this a compound to discuss with a physician rather than a self-directed research-compound decision.
CARS Trial Protocol (Moderate-Severe Stroke)
IV infusion
Daily infusion course over multiple weeks, administered in a clinical setting; exact volumes vary by trial arm
CAPTAIN Trial Protocol (Moderate TBI)
IV infusion
Multi-week course under clinical supervision, initiated post-injury
Vascular Dementia / Alzheimer's Adjunct
IV infusion, cyclical
Repeated courses over the disease course, per reviewed protocols
Cognitive-Optimization Use (Healthy Adults)
No trial data
No published dose-ranging study exists in this population; any protocol discussed for this use is extrapolated, not trial-derived
Clinical Monitoring
Validated Instruments Used in the Reviewed Trials
📊
Stroke Recovery
NIHSS · Barthel Index
Used in CARS and Cochrane-reviewed trials to grade neurological deficit and functional independence
🧠
TBI Recovery
GOS-E · executive function batteries
Glasgow Outcome Scale-Extended and standardized executive-function testing used in CAPTAIN trials
🧩
Dementia / Cognitive
MMSE · ADAS-Cog
Standard cognitive-decline instruments used across the vascular dementia/Alzheimer's adjunct literature
⚠️
Seizure Risk
Clinical screening required
EEG history and seizure-history screening before use, given the documented seizure-threshold effect
Safety Profile & Contraindications
Cochrane-Reported Serious Adverse Event Signal · Porcine-Derived Product
Cochrane 2023 Safety Signal: The systematic review found an approximately doubled risk of non-fatal serious adverse events in the Cerebrolysin arm compared to control across pooled stroke trials. This is a real, reviewed finding — not a theoretical concern — and should be weighed alongside any discussion of benefit.
⚡
Seizure Disorder
Contraindicated
Can lower seizure threshold in susceptible individuals; active seizure disorder is a contraindication
🫘
Renal Impairment
Caution — renal clearance
Severe renal impairment warrants dose reconsideration and physician oversight
🐖
Porcine Allergy
Contraindicated
Derived from porcine brain tissue; confirmed porcine allergy is a contraindication
🤰
Pregnancy / Breastfeeding
Suppressed — no data
No controlled human safety data exists for pregnancy or lactation
🎗️
Active Malignancy
Suppressed pending oncology input
Neurotrophic signaling in oncology contexts is not well-characterized
💉
Injection Site
Soreness, warmth, nodules possible
IM volume can cause local reactions; site rotation is standard practice
Candidate Framework
Who a Physician Discussion Is Most and Least Appropriate For
✓Reasonable to Discuss With a Physician
History of stroke or moderate TBI with an interest in continued recovery support, in coordination with treating neurology team
Documented vascular dementia or Alzheimer's diagnosis considering adjunct options with their physician
No seizure history, no porcine allergy, no active malignancy, not pregnant/breastfeeding
✕Poor Candidate / Higher Caution
Healthy adult seeking cognitive enhancement with no neurological injury — the least-evidenced use case for this specific compound
Active seizure disorder, confirmed porcine allergy, or active malignancy
Pregnant, breastfeeding, or trying to conceive
Unable to verify authenticity/cold-chain handling of the specific product being considered
What Would Resolve the Cerebrolysin Question
Level I Evidence Exists — The Open Question Is Interpretation, Not Absence
V
Preclinical
Mechanistic rationale for neurotrophic mimicry — established
IIb
Adjunct dementia/Alzheimer's systematic reviews
Modest, bounded benefit reported — established
Ib
CARS pooled analysis, CAPTAIN trials
Favorable in narrower subgroups (moderate-severe stroke, moderate TBI) — established
The highest-tier synthesis available does not support broad use in acute ischemic stroke
🔬
Population Specificity Needed
Future trials would need to isolate the moderate-to-severe stroke subgroup where CARS data looked more favorable, rather than pooling across all stroke severities as the broader Cochrane review does.
🧬
Healthy-Adult Data Gap
No dose-ranging or safety trial exists in healthy adults for cognitive-optimization use — this population has essentially no direct evidence base at any level.
📉
Adverse Event Signal Needs Explanation
The doubled serious-AE finding in the Cochrane review needs a mechanistic and trial-design explanation before broader use can be responsibly recommended.
🏭
Standardization Verification
As a multi-component biological, batch-to-batch consistency verification independent of the manufacturer would strengthen confidence in what is actually being studied trial-to-trial.
No. Cerebrolysin has no FDA-approved indication in the United States, and no FDA New Drug Application or Biologics License Application is on file for it. It does carry marketing approval as a prescription biologic in more than 50 international markets — including Russia, China, Austria, and Germany — for stroke, traumatic brain injury, and vascular dementia. In the US it is discussed and used only as a research/investigational preparation.
What does the clinical evidence actually show?
Cerebrolysin has real Level I evidence: a 2023 Cochrane systematic review pooling multiple randomized controlled trials in acute ischemic stroke. That review found moderate-certainty evidence of no significant reduction in death or dependency, alongside an approximately doubled risk of non-fatal serious adverse events versus placebo. Narrower pooled data (CARS-1/CARS-2) reported better motor-recovery outcomes specifically in moderate-to-severe stroke, and the CAPTAIN trials reported benefit in moderate TBI — but the highest-tier synthesis is not favorable for broad use.
Is it legal to obtain in the US?
Cerebrolysin is not a scheduled or banned substance, but because it has no FDA approval, it cannot be legally marketed for human treatment in the US and is typically sourced through compounding channels rather than a standard pharmacy. As a multi-component porcine-derived biologic rather than a single synthesized peptide, it carries substantiated counterfeit risk, so sourcing decisions should go through a licensed physician or pharmacy able to verify authenticity and chain of custody.
How is Cerebrolysin administered in clinical use?
In every published clinical trial reviewed on this page — CARS, CAPTAIN, and the trials in the Cochrane review — Cerebrolysin was given as an IV infusion in a hospital or clinical setting under medical supervision, not self-administered. A lower-volume intramuscular route is discussed in the research-compound literature but has never been evaluated in a randomized trial. This page does not provide self-injection guidance; administration route, dosing, and candidacy should be determined by a licensed physician.
What are the main safety concerns?
The 2023 Cochrane review found an approximately doubled risk of non-fatal serious adverse events in the Cerebrolysin arm versus control. Active seizure disorder, confirmed porcine allergy, and pregnancy or breastfeeding are contraindications; renal impairment and active malignancy warrant physician oversight. Because it is derived from porcine brain tissue rather than synthesized as a single defined peptide, it also carries higher counterfeit and authenticity risk than most compounds on this site.
How does Cerebrolysin compare to other neuroprotective peptides in this hub?
Cerebrolysin is unusual in the Cognitive Hub for having Level I evidence — a Cochrane systematic review — while compounds like Semax and Selank sit at Level IIb with a smaller Russian trial base, and Dihexa and Pinealon remain Level V, preclinical-only. Unlike those intranasal or oral compounds, Cerebrolysin is IM/IV-only and is a standardized mixture of neuropeptide fragments rather than one defined sequence — and it is the only compound in this hub with foreign regulatory approval for a specific clinical indication (stroke, TBI, vascular dementia), even without FDA approval.
SD
Dr. Scott DelBoccio, DMD
Author & Physician Reviewer · PeptideReport.ai
Dr. Scott DelBoccio, DMD is a retired dentist with thirty years of clinical practice — including a hormone-therapy and regenerative wellness practice built around individual bloodwork, national lecturing on advanced dental and surgical techniques, mentoring new dentists on practice management, and innovating dental and laser procedures now used throughout North America — who is now heavily involved in peptide research and development, building beginner-to-advanced optimization frameworks calibrated to the individual, and holds workshops and lectures on peptide therapeutics for other clinicians and researchers. Cerebrolysin is a case in point — genuine Level I evidence exists, and the highest-tier synthesis of that evidence is not favorable for broad use. This profile is intended to inform a conversation with a licensed physician, not to replace one.